{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 3,
  "pageCount": 32,
  "prevPage": 2,
  "nextPage": 4,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 6,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/3",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-3",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.06,
        "y": 0.32
      },
      "kind": "list",
      "text": "Approved incremental $75M to existing $250M program initiated Sept’22, with goal to complete program by end of 2023. Repurchased $155M of stock to date, including $27M in 2023. $170M remains in capital return program; expected to complete by end of 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "25ee41fe-3e50-48fb-a30d-ae3d3607ab1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.66,
        "y": 0.32
      },
      "kind": "list",
      "text": "Appointed independent directors Susannah Gray and Jim Kelly to Board of Directors. Part of ongoing commitment to board refreshment. Lead Independent Director William D. Young will not stand for re-election at 2023 AGM. Company has put forth proposal to declassify the Board of Directors over time at 2023 AGM",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "90ae459b-c94f-487e-ad12-c5ba4a961220",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.36,
        "y": 0.32
      },
      "kind": "list",
      "text": "Prioritize resource allocation toward ampreloxetine Phase 3 study and YUPELRI (revefenacin) PIFR-2 study. Discontinued research activities, including stopping inhaled Janus kinase (JAK) inhibitor program. ~17% headcount reduction completed by end of Mar 2023",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d371802a-d18b-4d7c-bf57-3ffe120511ce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.66,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Board and Governance Evolution",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1bf846c9-1a0d-45a1-a9b5-14a99aed79c1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.36,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Discontinued Investments in Research",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "85939f69-1d1c-4fd0-b8f0-a6f15bc3eb15",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.28,
        "x": 0.06,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Authorized $325M Capital Return Program",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "919d58f6-2d2d-4136-ba64-a939bea97232",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Strategic Actions Focused on Continued Value Creation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9a33e03a-0b3c-46d6-9a19-6fec63520c53",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Call to action",
      "slug": "call-to-action",
      "agent": null,
      "layer": "slide",
      "matchId": "909ea9a7-5886-4d76-adf0-9e0639f1be27",
      "evidence": "Authorized $325M Capital Return Program",
      "confidence": 0.5
    },
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "5a626cea-4a8d-4fb5-aa5c-72f87e0a909f",
      "evidence": "list/bullet: Appointed independent directors Susannah Gray and Jim Kelly to Board of Directors.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 3,
      "beatId": "dd87dbb1-9f4f-4a83-b015-29179ef31cab",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Key Messages",
      "beatSlug": null,
      "evidence": "The deck emphasizes strategic actions focused on continued value creation and 2023 targets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 4,
      "from": 3,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "0d365f14-2dce-441e-b9c2-35afc75c3362",
      "evidence": "The deck emphasizes the company's focus on growing YUPELRI sales and developing new treatments.",
      "position": 1,
      "objective": "What are the company's strategic actions for continued value creation?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.7,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}